{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:06:59Z","timestamp":1792897619499,"version":"4.5.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81974530"],"award-info":[{"award-number":["81974530"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81974530"],"award-info":[{"award-number":["81974530"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81974530"],"award-info":[{"award-number":["81974530"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hubei International Sciencific and Technological Cooperation Project","award":["2022EHB039"],"award-info":[{"award-number":["2022EHB039"]}]},{"name":"Hubei International Sciencific and Technological Cooperation Project","award":["2022EHB039"],"award-info":[{"award-number":["2022EHB039"]}]},{"name":"Hubei International Sciencific and Technological Cooperation Project","award":["2022EHB039"],"award-info":[{"award-number":["2022EHB039"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In recent years, viral pneumonia has become a significant challenge to global public health, particularly during the COVID-19 pandemic. Viral pneumonia can be caused by various viruses, including influenza virus, RSV, and adenovirus. These viruses trigger inflammatory responses by invading the respiratory epithelial cells, leading to lung damage. Existing antiviral drugs such as ribavirin, adobiravir, and oseltamivir exert their therapeutic effects by inhibiting different stages of the viral life cycle but face issues such as increasing drug resistance. Natural components like astragalus saponins, Houttuynia cordata flavonoids, and tea theaflavin-gallates have demonstrated supportive roles in antiviral treatments, capable of not only enhancing immune responses but also potentially inhibiting viral replication through multiple pathways, thereby alleviating lung damage. Although natural components cannot entirely replace traditional antiviral drugs, their role in comprehensive treatment regimens is becoming increasingly important. This review summarizes the current applications and limitations of antiviral drugs and explores the research progress and potential mechanisms of natural components in the treatment of viral pneumonia.<\/jats:p>","DOI":"10.1186\/s12985-025-02666-1","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T08:22:52Z","timestamp":1741249372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Antiviral treatment for viral pneumonia: current drugs and natural compounds"],"prefix":"10.1186","volume":"22","author":[{"given":"Hao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Thi Thu","family":"Hien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkin","family":"Musabaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khrystyna","family":"Pronyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhide","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"1","key":"2666_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.idc.2023.12.009","volume":"38","author":"J Febbo","year":"2024","unstructured":"Febbo J, Revels J, Ketai L. Viral pneumonias. Infect Dis Clin North Am. 2024;38(1):163\u201382. https:\/\/doi.org\/10.1016\/j.idc.2023.12.009.","journal-title":"Infect Dis Clin North Am"},{"key":"2666_CR2","doi-asserted-by":"publisher","first-page":"j2471","DOI":"10.1136\/bmj.j2471","volume":"358","author":"RG Wunderink","year":"2017","unstructured":"Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017;358:j2471. https:\/\/doi.org\/10.1136\/bmj.j2471.","journal-title":"BMJ"},{"issue":"1","key":"2666_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.idc.2023.12.010","volume":"38","author":"R Cavallazzi","year":"2024","unstructured":"Cavallazzi R, Ramirez JA. Influenza and viral pneumonia. Infect Dis Clin North Am. 2024;38(1):183\u2013212. https:\/\/doi.org\/10.1016\/j.idc.2023.12.010.","journal-title":"Infect Dis Clin North Am"},{"issue":"10","key":"2666_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.tim.2011.07.003","volume":"19","author":"CC Friedel","year":"2011","unstructured":"Friedel CC, Haas J. Virus-host interactomes and global models of virus-infected cells. Trends Microbiol. 2011;19(10):501\u20138. https:\/\/doi.org\/10.1016\/j.tim.2011.07.003.","journal-title":"Trends Microbiol"},{"issue":"10","key":"2666_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/s0966-842x(00)01824-2","volume":"8","author":"B Sodeik","year":"2000","unstructured":"Sodeik B. Mechanisms of viral transport in the cytoplasm. Trends Microbiol. 2000;8(10):465\u201372. https:\/\/doi.org\/10.1016\/s0966-842x(00)01824-2.","journal-title":"Trends Microbiol"},{"key":"2666_CR6","doi-asserted-by":"publisher","unstructured":"International committee on taxonomy of viruses executive committee. The new scope of virus taxonomy: partitioning the virosphere into 15 hierarchical ranks. Nat Microbiol. 2020;5(5):668-674. https:\/\/doi.org\/10.1038\/s41564-020-0709-x","DOI":"10.1038\/s41564-020-0709-x"},{"key":"2666_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev.biochem.78.082207.084029","volume":"78","author":"PM Colman","year":"2009","unstructured":"Colman PM. New antivirals and drug resistance. Annu Rev Biochem. 2009;78:95\u2013118. https:\/\/doi.org\/10.1146\/annurev.biochem.78.082207.084029.","journal-title":"Annu Rev Biochem"},{"key":"2666_CR8","doi-asserted-by":"publisher","first-page":"582322","DOI":"10.3389\/fphar.2020.582322","volume":"11","author":"S Xi","year":"2020","unstructured":"Xi S, Li Y, Yue L, et al. Role of traditional Chinese medicine in the management of viral pneumonia. Front Pharmacol. 2020;11:582322. https:\/\/doi.org\/10.3389\/fphar.2020.582322.","journal-title":"Front Pharmacol"},{"key":"2666_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122027","volume":"330","author":"SK Tirunavalli","year":"2023","unstructured":"Tirunavalli SK, Pramatha S, Eedara AC, et al. Protective effect of \u03b2-glucan on Poly(I:C)-induced acute lung injury\/inflammation: therapeutic implications of viral infections in the respiratory system. Life Sci. 2023;330: 122027. https:\/\/doi.org\/10.1016\/j.lfs.2023.122027.","journal-title":"Life Sci"},{"issue":"10","key":"2666_CR10","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1128\/AAC.01098-15","volume":"59","author":"H Traboulsi","year":"2015","unstructured":"Traboulsi H, Cloutier A, Boyapelly K, et al. The flavonoid isoliquiritigenin reduces lung inflammation and mouse morbidity during influenza virus infection. Antimicrob Agents Chemother. 2015;59(10):6317\u201327. https:\/\/doi.org\/10.1128\/AAC.01098-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2666_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.antiviral.2006.04.014","volume":"74","author":"TY Ho","year":"2007","unstructured":"Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2007;74(2):92\u2013101. https:\/\/doi.org\/10.1016\/j.antiviral.2006.04.014.","journal-title":"Antiviral Res"},{"issue":"9","key":"2666_CR12","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1021\/acs.jcim.3c00409","volume":"63","author":"LC Saramago","year":"2023","unstructured":"Saramago LC, Santana MV, Gomes BF, et al. AI-driven discovery of SARS-CoV-2 main protease fragment-like inhibitors with antiviral activity in vitro. J Chem Inf Model. 2023;63(9):2866\u201380. https:\/\/doi.org\/10.1021\/acs.jcim.3c00409.","journal-title":"J Chem Inf Model"},{"key":"2666_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/dom.13417","volume":"20","author":"HJL Heerspink","year":"2018","unstructured":"Heerspink HJL, List J, Perkovic V. New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. Diabetes Obes Metab. 2018;20:14\u20138. https:\/\/doi.org\/10.1111\/dom.13417.","journal-title":"Diabetes Obes Metab"},{"issue":"6387","key":"2666_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1126\/science.aaq0179","volume":"360","author":"JS Gootenberg","year":"2018","unstructured":"Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science. 2018;360(6387):439\u201344. https:\/\/doi.org\/10.1126\/science.aaq0179.","journal-title":"Science"},{"issue":"1","key":"2666_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","volume":"19","author":"S Nooraei","year":"2021","unstructured":"Nooraei S, Bahrulolum H, Hoseini ZS, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology. 2021;19(1):59. https:\/\/doi.org\/10.1186\/s12951-021-00806-7.","journal-title":"J Nanobiotechnology"},{"key":"2666_CR16","doi-asserted-by":"publisher","unstructured":"Pletz MW, Bauer M, Brakhage AA. One step closer to precision medicine for infectious diseases [published correction appears in Lancet Infect Dis. 2019 Aug;19(8):e259. https:\/\/doi.org\/10.1016\/S1473-3099(19)30344-5]. Lancet Infect Dis. 2019;19(6):564\u2013565. https:\/\/doi.org\/10.1016\/S1473-3099(19)30070-2","DOI":"10.1016\/S1473-3099(19)30344-5 10.1016\/S1473-3099(19)30070-2"},{"issue":"1","key":"2666_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0163-7258(79)90058-5","volume":"6","author":"RW Sidwell","year":"1979","unstructured":"Sidwell RW, Robins RK, Hillyard IW. Ribavirin: an antiviral agent. Pharmacol Ther. 1979;6(1):123\u201346. https:\/\/doi.org\/10.1016\/0163-7258(79)90058-5.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"2666_CR18","first-page":"218","volume":"3","author":"HS Te","year":"2007","unstructured":"Te HS, Randall G, Jensen DM. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol (N Y). 2007;3(3):218\u201325.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"1","key":"2666_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/rmv.483","volume":"16","author":"JD Graci","year":"2006","unstructured":"Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol. 2006;16(1):37\u201348. https:\/\/doi.org\/10.1002\/rmv.483.","journal-title":"Rev Med Virol"},{"issue":"17","key":"2666_CR20","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMc0905290","volume":"361","author":"KM Chan-Tack","year":"2009","unstructured":"Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med. 2009;361(17):1713\u20134. https:\/\/doi.org\/10.1056\/NEJMc0905290.","journal-title":"N Engl J Med"},{"issue":"6","key":"2666_CR21","doi-asserted-by":"publisher","first-page":"CD003216","DOI":"10.1002\/14651858.CD003216.pub2","volume":"2014","author":"G Langer","year":"2014","unstructured":"Langer G, Fink A. Nutritional interventions for preventing and treating pressure ulcers. Cochrane Database Syst Rev. 2014;2014(6):CD003216. https:\/\/doi.org\/10.1002\/14651858.CD003216.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2666_CR22","doi-asserted-by":"publisher","first-page":"l5021","DOI":"10.1136\/bmj.l5021","volume":"366","author":"HH Nam","year":"2019","unstructured":"Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019;366:l5021. https:\/\/doi.org\/10.1136\/bmj.l5021.","journal-title":"BMJ"},{"issue":"2","key":"2666_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/tid.12194","volume":"16","author":"JR Marcelin","year":"2014","unstructured":"Marcelin JR, Wilson JW, Razonable RR. Mayo clinic hematology\/oncology and transplant infectious diseases services. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis. 2014;16(2):242\u201350. https:\/\/doi.org\/10.1111\/tid.12194.","journal-title":"Transpl Infect Dis"},{"issue":"Suppl 1","key":"2666_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1478-3231.2008.01936.x","volume":"29","author":"ML Shiffman","year":"2009","unstructured":"Shiffman ML. What future for ribavirin? Liver Int. 2009;29(Suppl 1):68\u201373. https:\/\/doi.org\/10.1111\/j.1478-3231.2008.01936.x.","journal-title":"Liver Int"},{"issue":"8","key":"2666_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.984","volume":"11","author":"Y Kang","year":"2023","unstructured":"Kang Y, Shi Y, Xu S. Arbidol: the current demand, strategies, and antiviral mechanisms. Immun Inflamm Dis. 2023;11(8): e984. https:\/\/doi.org\/10.1002\/iid3.984.","journal-title":"Immun Inflamm Dis"},{"key":"2666_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","volume":"107","author":"J Blaising","year":"2014","unstructured":"Blaising J, Polyak SJ, P\u00e9cheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014;107:84\u201394. https:\/\/doi.org\/10.1016\/j.antiviral.2014.04.006.","journal-title":"Antiviral Res"},{"issue":"10","key":"2666_CR27","doi-asserted-by":"publisher","first-page":"a038638","DOI":"10.1101\/cshperspect.a038638","volume":"11","author":"SJ Gamblin","year":"2021","unstructured":"Gamblin SJ, Vachieri SG, Xiong X, Zhang J, Martin SR, Skehel JJ. Hemagglutinin structure and activities. Cold Spring Harb Perspect Med. 2021;11(10):a038638. https:\/\/doi.org\/10.1101\/cshperspect.a038638.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"2666_CR28","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","volume":"81","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19. J Infect. 2020;81(1):e21\u20133. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.060.","journal-title":"J Infect"},{"issue":"18","key":"2666_CR29","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2020.6019","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824\u201336. https:\/\/doi.org\/10.1001\/jama.2020.6019.","journal-title":"JAMA"},{"issue":"1","key":"2666_CR30","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","volume":"81","author":"L Deng","year":"2020","unstructured":"Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV\/r versus LPV\/r alone against corona virus disease 2019: a retrospective cohort study. J Infect. 2020;81(1):e1\u20135. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.002.","journal-title":"J Infect"},{"issue":"1","key":"2666_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.medj.2020.04.001","volume":"1","author":"Y Li","year":"2020","unstructured":"Li Y, Xie Z, Lin W, et al. Efficacy and safety of lopinavir\/ritonavir or arbidol in adult patients with mild\/moderate COVID-19: an exploratory randomized controlled trial. Med. 2020;1(1):105-113.e4. https:\/\/doi.org\/10.1016\/j.medj.2020.04.001.","journal-title":"Med"},{"issue":"3","key":"2666_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1128\/AAC.31.3.361","volume":"31","author":"D Gold","year":"1987","unstructured":"Gold D, Corey L. Acyclovir prophylaxis for herpes simplex virus infection. Antimicrob Agents Chemother. 1987;31(3):361\u20137. https:\/\/doi.org\/10.1128\/AAC.31.3.361.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2666_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2165\/00003495-198937030-00002","volume":"37","author":"JJ O\u2019Brien","year":"1989","unstructured":"O\u2019Brien JJ, Campoli-Richards DM. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989;37(3):233\u2013309. https:\/\/doi.org\/10.2165\/00003495-198937030-00002.","journal-title":"Drugs"},{"issue":"5","key":"2666_CR34","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2165\/00003495-198326050-00002","volume":"26","author":"DM Richards","year":"1983","unstructured":"Richards DM, Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1983;26(5):378\u2013438. https:\/\/doi.org\/10.2165\/00003495-198326050-00002.","journal-title":"Drugs"},{"issue":"11","key":"2666_CR35","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/qjmed\/hcy124","volume":"111","author":"JD Duke","year":"2018","unstructured":"Duke JD, Sagar AS. Varicella pneumonia. QJM. 2018;111(11):827. https:\/\/doi.org\/10.1093\/qjmed\/hcy124.","journal-title":"QJM"},{"issue":"12","key":"2666_CR36","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1177\/0885066620965941","volume":"36","author":"ME Jellinge","year":"2021","unstructured":"Jellinge ME, Hansen F, Coia JE, Song Z. Herpes simplex virus type 1 pneumonia-a review. J Intensive Care Med. 2021;36(12):1398\u2013402. https:\/\/doi.org\/10.1177\/0885066620965941.","journal-title":"J Intensive Care Med"},{"issue":"Suppl 1","key":"2666_CR37","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1093\/infdis\/jiz493","volume":"221","author":"E Acosta","year":"2020","unstructured":"Acosta E, Bowlin T, Brooks J, et al. Advances in the development of therapeutics for cytomegalovirus infections. J Infect Dis. 2020;221(Suppl 1):S32\u201344. https:\/\/doi.org\/10.1093\/infdis\/jiz493.","journal-title":"J Infect Dis"},{"issue":"4","key":"2666_CR38","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2165\/00003495-199039040-00008","volume":"39","author":"D Faulds","year":"1990","unstructured":"Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39(4):597\u2013638. https:\/\/doi.org\/10.2165\/00003495-199039040-00008.","journal-title":"Drugs"},{"issue":"3","key":"2666_CR39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2165\/00003495-199448030-00009","volume":"48","author":"A Markham","year":"1994","unstructured":"Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs. 1994;48(3):455\u201384. https:\/\/doi.org\/10.2165\/00003495-199448030-00009.","journal-title":"Drugs"},{"issue":"6","key":"2666_CR40","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1086\/517002","volume":"25","author":"MA Jacobson","year":"1997","unstructured":"Jacobson MA. Ganciclovir therapy for severe cytomegalovirus infection in immunocompetent patients. Clin Infect Dis. 1997;25(6):1487\u20138. https:\/\/doi.org\/10.1086\/517002.","journal-title":"Clin Infect Dis"},{"issue":"9950","key":"2666_CR41","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/S0140-6736(14)61761-X","volume":"384","author":"C Del Mar","year":"2014","unstructured":"Del Mar C, Doshi P, Hama R, et al. Neuraminidase inhibitors for influenza complications. Lancet. 2014;384(9950):1260\u20131. https:\/\/doi.org\/10.1016\/S0140-6736(14)61761-X.","journal-title":"Lancet"},{"issue":"4","key":"2666_CR42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1750-2659.2011.00304.x","volume":"6","author":"GM Air","year":"2012","unstructured":"Air GM. Influenza neuraminidase. Influenza Other Respir Viruses. 2012;6(4):245\u201356. https:\/\/doi.org\/10.1111\/j.1750-2659.2011.00304.x.","journal-title":"Influenza Other Respir Viruses"},{"key":"2666_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105719","volume":"218","author":"R Gao","year":"2023","unstructured":"Gao R, Pascua PNQ, Nguyen HT, et al. New insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses. Antiviral Res. 2023;218: 105719. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105719.","journal-title":"Antiviral Res"},{"issue":"4","key":"2666_CR44","doi-asserted-by":"publisher","first-page":"e95865","DOI":"10.1371\/journal.pone.0095865","volume":"9","author":"HL Hong","year":"2014","unstructured":"Hong HL, Hong SB, Ko GB, et al. Viral infection is not uncommon in adult patients with severe hospital-acquired pneumonia. PLoS One. 2014;9(4):e95865. https:\/\/doi.org\/10.1371\/journal.pone.0095865.","journal-title":"PLoS One"},{"issue":"3","key":"2666_CR45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1001\/jamainternmed.2016.0016","volume":"176","author":"P Doshi","year":"2016","unstructured":"Doshi P, Jefferson T. Neuraminidase inhibitors and influenza infection. JAMA Intern Med. 2016;176(3):415\u20136. https:\/\/doi.org\/10.1001\/jamainternmed.2016.0016.","journal-title":"JAMA Intern Med"},{"key":"2666_CR46","doi-asserted-by":"publisher","first-page":"g2548","DOI":"10.1136\/bmj.g2548","volume":"348","author":"HM Krumholz","year":"2014","unstructured":"Krumholz HM. Neuraminidase inhibitors for influenza. BMJ. 2014;348:g2548. https:\/\/doi.org\/10.1136\/bmj.g2548.","journal-title":"BMJ"},{"key":"2666_CR47","doi-asserted-by":"publisher","unstructured":"Ebell MH. WHO downgrades status of oseltamivir [published correction appears in BMJ. 2017 Nov 14;359:j5281. https:\/\/doi.org\/10.1136\/bmj.j5281]. BMJ. 2017;358:j3266. Published 2017 Jul 12. https:\/\/doi.org\/10.1136\/bmj.j3266","DOI":"10.1136\/bmj.j5281 10.1136\/bmj.j3266"},{"issue":"9979","key":"2666_CR48","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(15)60074-5","volume":"385","author":"H Kelly","year":"2015","unstructured":"Kelly H, Cowling BJ. Influenza: the rational use of oseltamivir. Lancet. 2015;385(9979):1700\u20132. https:\/\/doi.org\/10.1016\/S0140-6736(15)60074-5.","journal-title":"Lancet"},{"key":"2666_CR49","doi-asserted-by":"publisher","first-page":"g2545","DOI":"10.1136\/bmj.g2545","volume":"348","author":"T Jefferson","year":"2014","unstructured":"Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2545. https:\/\/doi.org\/10.1136\/bmj.g2545.","journal-title":"BMJ"},{"issue":"2","key":"2666_CR50","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/00003495-200161020-00011","volume":"61","author":"K McClellan","year":"2001","unstructured":"McClellan K, Perry CM. Oseltamivir: a review of its use in influenza [published correction appears in Drugs 2001;61(6):775]. Drugs. 2001;61(2):263\u201383. https:\/\/doi.org\/10.2165\/00003495-200161020-00011.","journal-title":"Drugs"},{"issue":"4","key":"2666_CR51","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1086\/505868","volume":"43","author":"N Kawai","year":"2006","unstructured":"Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003\u20132004 and 2004\u20132005 influenza seasons. Clin Infect Dis. 2006;43(4):439\u201344. https:\/\/doi.org\/10.1086\/505868.","journal-title":"Clin Infect Dis"},{"issue":"10217","key":"2666_CR52","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(19)32982-4","volume":"395","author":"CC Butler","year":"2020","unstructured":"Butler CC, van der Velden AW, Bongard E, et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet. 2020;395(10217):42\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(19)32982-4.","journal-title":"Lancet"},{"issue":"8","key":"2666_CR53","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.drudis.2020.06.004","volume":"25","author":"S Kumar","year":"2020","unstructured":"Kumar S, Goicoechea S, Kumar S, et al. Oseltamivir analogs with potent anti-influenza virus activity. Drug Discov Today. 2020;25(8):1389\u2013402. https:\/\/doi.org\/10.1016\/j.drudis.2020.06.004.","journal-title":"Drug Discov Today"},{"issue":"7211","key":"2666_CR54","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1136\/bmj.319.7211.655","volume":"319","author":"JS Nguyen-Van-Tam","year":"1999","unstructured":"Nguyen-Van-Tam JS. Zanamivir for influenza: a public health perspective. Its use will require careful management by GPs. BMJ. 1999;319(7211):655\u20136. https:\/\/doi.org\/10.1136\/bmj.319.7211.655.","journal-title":"BMJ"},{"key":"2666_CR55","doi-asserted-by":"publisher","first-page":"c131","DOI":"10.1136\/bmj.c131","volume":"340","author":"BA Eagel","year":"2010","unstructured":"Eagel BA. The truth about Tamiflu? Zanamivir should be inhaled, not nebulised. BMJ. 2010;340:c131. https:\/\/doi.org\/10.1136\/bmj.c131.","journal-title":"BMJ."},{"issue":"12","key":"2666_CR56","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1086\/518385","volume":"44","author":"N Kawai","year":"2007","unstructured":"Kawai N, Ikematsu H, Iwaki N, et al. Zanamivir treatment is equally effective for both influenza A and influenza B. Clin Infect Dis. 2007;44(12):1666. https:\/\/doi.org\/10.1086\/518385.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2666_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4155\/tde.15.9","volume":"6","author":"S Shanmugam","year":"2015","unstructured":"Shanmugam S. Zanamivir oral delivery: possibilities revisited. Ther Deliv. 2015;6(4):403\u20135. https:\/\/doi.org\/10.4155\/tde.15.9.","journal-title":"Ther Deliv"},{"key":"2666_CR58","doi-asserted-by":"publisher","first-page":"g2547","DOI":"10.1136\/bmj.g2547","volume":"348","author":"CJ Heneghan","year":"2014","unstructured":"Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2547. https:\/\/doi.org\/10.1136\/bmj.g2547.","journal-title":"BMJ"},{"key":"2666_CR59","doi-asserted-by":"publisher","unstructured":"Peramivir for influenza. Aust Prescr. 2019;42(4):143. https:\/\/doi.org\/10.18773\/austprescr.2019.047","DOI":"10.18773\/austprescr.2019.047"},{"issue":"6","key":"2666_CR60","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1517\/13543784.11.6.859","volume":"11","author":"RW Sidwell","year":"2002","unstructured":"Sidwell RW, Smee DF. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin Investig Drugs. 2002;11(6):859\u201369. https:\/\/doi.org\/10.1517\/13543784.11.6.859.","journal-title":"Expert Opin Investig Drugs"},{"key":"2666_CR61","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fmicb.2016.00450","volume":"7","author":"MM Alame","year":"2016","unstructured":"Alame MM, Massaad E, Zaraket H. Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections. Front Microbiol. 2016;7:450. https:\/\/doi.org\/10.3389\/fmicb.2016.00450.","journal-title":"Front Microbiol"},{"key":"2666_CR62","doi-asserted-by":"publisher","unstructured":"Scott LJ. Peramivir: a review in uncomplicated influenza [published correction appears in Drugs. 2018 Sep;78(14):1525. https:\/\/doi.org\/10.1007\/s40265-018-0986-3]. Drugs. 2018;78(13):1363\u20131370. https:\/\/doi.org\/10.1007\/s40265-018-0981-8","DOI":"10.1007\/s40265-018-0986-3 10.1007\/s40265-018-0981-8"},{"issue":"11","key":"2666_CR63","doi-asserted-by":"publisher","first-page":"CD002745","DOI":"10.1002\/14651858.CD002745.pub4","volume":"2014","author":"MG Alves Galv\u00e3o","year":"2014","unstructured":"Alves Galv\u00e3o MG, Rocha Crispino Santos MA, Alves da Cunha AJ. Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst Rev. 2014;2014(11):CD002745. https:\/\/doi.org\/10.1002\/14651858.CD002745.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"2666_CR64","doi-asserted-by":"publisher","first-page":"001169","DOI":"10.1002\/14651858.CD001169.pub3","volume":"2","author":"T Jefferson","year":"2006","unstructured":"Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev. 2006;2:001169. https:\/\/doi.org\/10.1002\/14651858.CD001169.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2666_CR65","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s13238-010-0025-y","volume":"1","author":"RM Pielak","year":"2010","unstructured":"Pielak RM, Chou JJ. Flu channel drug resistance: a tale of two sites. Protein Cell. 2010;1(3):246\u201358. https:\/\/doi.org\/10.1007\/s13238-010-0025-y.","journal-title":"Protein Cell"},{"issue":"1","key":"2666_CR66","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0163-7258(92)90038-2","volume":"56","author":"AN McNair","year":"1992","unstructured":"McNair AN, Kerr IM. Viral inhibition of the interferon system. Pharmacol Ther. 1992;56(1):79\u201395. https:\/\/doi.org\/10.1016\/0163-7258(92)90038-2.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"2666_CR67","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/v9080223","volume":"9","author":"JM Shim","year":"2017","unstructured":"Shim JM, Kim J, Tenson T, Min JY, Kainov DE. Influenza virus infection, interferon response, viral counter-response, and apoptosis. Viruses. 2017;9(8):223. https:\/\/doi.org\/10.3390\/v9080223.","journal-title":"Viruses"},{"issue":"6504","key":"2666_CR68","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1126\/science.abd2208","volume":"369","author":"GE Grajales-Reyes","year":"2020","unstructured":"Grajales-Reyes GE, Colonna M. Interferon responses in viral pneumonias. Science. 2020;369(6504):626\u20137. https:\/\/doi.org\/10.1126\/science.abd2208.","journal-title":"Science"},{"issue":"6","key":"2666_CR69","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/v16060933","volume":"16","author":"N J\u00e4ger","year":"2024","unstructured":"J\u00e4ger N, P\u00f6hlmann S, Rodnina MV, Ayyub SA. Interferon-stimulated genes that target retrovirus translation. Viruses. 2024;16(6):933. https:\/\/doi.org\/10.3390\/v16060933.","journal-title":"Viruses"},{"issue":"6","key":"2666_CR70","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1002\/med.21707","volume":"40","author":"ZJ Zhang","year":"2020","unstructured":"Zhang ZJ, Morris-Natschke SL, Cheng YY, Lee KH, Li RT. Development of anti-influenza agents from natural products. Med Res Rev. 2020;40(6):2290\u2013338. https:\/\/doi.org\/10.1002\/med.21707.","journal-title":"Med Res Rev"},{"issue":"9","key":"2666_CR71","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/ptr.5188","volume":"28","author":"J Fu","year":"2014","unstructured":"Fu J, Wang Z, Huang L, et al. Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi). Phytother Res. 2014;28(9):1275\u201383. https:\/\/doi.org\/10.1002\/ptr.5188.","journal-title":"Phytother Res"},{"issue":"12","key":"2666_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/jfbc.13510","volume":"44","author":"Q Wu","year":"2020","unstructured":"Wu Q, Hu Y. Integrated network pharmacology and molecular docking strategy to explore the mechanism of medicinal and edible astragali radix-atractylodis macrocephalae rhizoma acting on pneumonia via immunomodulation. J Food Biochem. 2020;44(12): e13510. https:\/\/doi.org\/10.1111\/jfbc.13510.","journal-title":"J Food Biochem"},{"issue":"16","key":"2666_CR73","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.3390\/molecules28166118","volume":"28","author":"Y Liang","year":"2023","unstructured":"Liang Y, Chen B, Liang D, et al. Pharmacological effects of astragaloside IV: a review. Molecules. 2023;28(16):6118. https:\/\/doi.org\/10.3390\/molecules28166118.","journal-title":"Molecules"},{"issue":"6","key":"2666_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1309","volume":"12","author":"X Huang","year":"2024","unstructured":"Huang X, Zhou Y, Li Y, et al. Astragaloside IV inhibits inflammation caused by influenza virus via reactive oxygen species\/NOD-like receptor thermal protein domain associated protein 3\/Caspase-1 signaling pathway. Immun Inflamm Dis. 2024;12(6): e1309. https:\/\/doi.org\/10.1002\/iid3.1309.","journal-title":"Immun Inflamm Dis"},{"key":"2666_CR75","doi-asserted-by":"publisher","first-page":"e12203","DOI":"10.1590\/1414-431X2023e12203","volume":"56","author":"L Li","year":"2023","unstructured":"Li L, Guan J, Lin R, et al. Astragaloside IV alleviates lung inflammation in Klebsiella pneumonia rats by suppressing TGF-\u03b21\/Smad pathway. Braz J Med Biol Res. 2023;56:e12203. https:\/\/doi.org\/10.1590\/1414-431X2023e12203.","journal-title":"Braz J Med Biol Res"},{"issue":"9","key":"2666_CR76","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/ph15091079","volume":"15","author":"S Rafiq","year":"2022","unstructured":"Rafiq S, Hao H, Ijaz M, Raza A. Pharmacological effects of houttuynia cordata thunb (H. cordata): a comprehensive review. Pharmaceuticals. 2022;15(9):1079. https:\/\/doi.org\/10.3390\/ph15091079.","journal-title":"Pharmaceuticals"},{"issue":"8","key":"2666_CR77","doi-asserted-by":"publisher","first-page":"e10386","DOI":"10.1016\/j.heliyon.2022.e10386","volume":"8","author":"C Laldinsangi","year":"2022","unstructured":"Laldinsangi C. The therapeutic potential of Houttuynia cordata: a current review. Heliyon. 2022;8(8):e10386. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e10386.","journal-title":"Heliyon"},{"key":"2666_CR78","doi-asserted-by":"publisher","first-page":"155195","DOI":"10.1016\/j.phymed.2023.155195","volume":"123","author":"P Wei","year":"2024","unstructured":"Wei P, Luo Q, Hou Y, Zhao F, Li F, Meng Q. Houttuynia Cordata Thunb.: a comprehensive review of traditional applications, phytochemistry, pharmacology and safety. Phytomedicine. 2024;123:155195. https:\/\/doi.org\/10.1016\/j.phymed.2023.155195.","journal-title":"Phytomedicine"},{"key":"2666_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.153150","volume":"67","author":"LJ Ling","year":"2020","unstructured":"Ling LJ, Lu Y, Zhang YY, et al. Flavonoids from Houttuynia cordata attenuate H1N1-induced acute lung injury in mice via inhibition of influenza virus and Toll-like receptor signalling. Phytomedicine. 2020;67: 153150. https:\/\/doi.org\/10.1016\/j.phymed.2019.153150.","journal-title":"Phytomedicine"},{"key":"2666_CR80","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jep.2018.02.016","volume":"218","author":"H Zhu","year":"2018","unstructured":"Zhu H, Lu X, Ling L, et al. Houttuynia cordata polysaccharides ameliorate pneumonia severity and intestinal injury in mice with influenza virus infection. J Ethnopharmacol. 2018;218:90\u20139. https:\/\/doi.org\/10.1016\/j.jep.2018.02.016.","journal-title":"J Ethnopharmacol"},{"key":"2666_CR81","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ijbiomac.2022.09.015","volume":"221","author":"C Shi","year":"2022","unstructured":"Shi C, Zhou L, Li H, et al. Intestinal microbiota metabolizing Houttuynia cordata polysaccharides in H1N1 induced pneumonia mice contributed to Th17\/Treg rebalance in gut-lung axis. Int J Biol Macromol. 2022;221:288\u2013302. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.09.015.","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"2666_CR82","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s12272-015-0585-8","volume":"38","author":"JH Lee","year":"2015","unstructured":"Lee JH, Ahn J, Kim JW, Lee SG, Kim HP. Flavonoids from the aerial parts of Houttuynia cordata attenuate lung inflammation in mice. Arch Pharm Res. 2015;38(7):1304\u201311. https:\/\/doi.org\/10.1007\/s12272-015-0585-8.","journal-title":"Arch Pharm Res"},{"key":"2666_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2023.115469","volume":"233","author":"J Tang","year":"2023","unstructured":"Tang J, Zhou L, Yuan G, et al. Therapeutic effects on H1N1-induced pneumonia in mice and intestinal bacteria biotransformation of four main flavonoids from Houttuynia cordata Thunb. J Pharm Biomed Anal. 2023;233: 115469. https:\/\/doi.org\/10.1016\/j.jpba.2023.115469.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"2666_CR84","doi-asserted-by":"publisher","first-page":"1344521","DOI":"10.1080\/16546628.2017.1344521","volume":"61","author":"HF He","year":"2017","unstructured":"He HF. Research progress on theaflavins: efficacy, formation, and preparation. Food Nutr Res. 2017;61(1):1344521. https:\/\/doi.org\/10.1080\/16546628.2017.1344521.","journal-title":"Food Nutr Res"},{"key":"2666_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175332v","volume":"938","author":"M Sima","year":"2023","unstructured":"Sima M, Lv C, Qi J, et al. Anti-inflammatory effects of theaflavin-3\u2032-gallate during influenza virus infection through regulating the TLR4\/MAPK\/p38 pathway. Eur J Pharmacol. 2023;938: 175332. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175332v.","journal-title":"Eur J Pharmacol"},{"issue":"17","key":"2666_CR86","doi-asserted-by":"publisher","first-page":"9498","DOI":"10.3390\/ijms25179498","volume":"25","author":"CK Lu","year":"2024","unstructured":"Lu CK, Lung J, Shu LH, et al. The inhibiting effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-gallate on interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 variants. Int J Mol Sci. 2024;25(17):9498. https:\/\/doi.org\/10.3390\/ijms25179498.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"2666_CR87","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.3390\/molecules27144523","volume":"27","author":"RG Xiong","year":"2022","unstructured":"Xiong RG, Huang SY, Wu SX, et al. Anticancer effects and mechanisms of berberine from medicinal herbs: an update review. Molecules. 2022;27(14):4523. https:\/\/doi.org\/10.3390\/molecules27144523.","journal-title":"Molecules"},{"issue":"2","key":"2666_CR88","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/03602532.2017.1306544","volume":"49","author":"K Wang","year":"2017","unstructured":"Wang K, Feng X, Chai L, Cao S, Qiu F. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev. 2017;49(2):139\u201357. https:\/\/doi.org\/10.1080\/03602532.2017.1306544.","journal-title":"Drug Metab Rev"},{"issue":"7","key":"2666_CR89","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/ddr.21995","volume":"83","author":"C An","year":"2022","unstructured":"An C, Wu Y, Wu J, et al. Berberine ameliorates pulmonary inflammation in mice with influenza viral pneumonia by inhibiting NLRP3 inflammasome activation and gasdermin D-mediated pyroptosis. Drug Dev Res. 2022;83(7):1707\u201321. https:\/\/doi.org\/10.1002\/ddr.21995.","journal-title":"Drug Dev Res"},{"issue":"2","key":"2666_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.phyplu.2022.100252","volume":"2","author":"J Cao","year":"2022","unstructured":"Cao J, Li L, Xiong L, Wang C, Chen Y, Zhang X. Research on the mechanism of berberine in the treatment of COVID-19 pneumonia pulmonary fibrosis using network pharmacology and molecular docking. Phytomed Plus. 2022;2(2): 100252. https:\/\/doi.org\/10.1016\/j.phyplu.2022.100252.","journal-title":"Phytomed Plus"},{"issue":"6","key":"2666_CR91","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s11655-011-0640-3","volume":"17","author":"Y Wu","year":"2011","unstructured":"Wu Y, Li JQ, Kim YJ, Wu J, Wang Q, Hao Y. In vivo and in vitro antiviral effects of berberine on influenza virus. Chin J Integr Med. 2011;17(6):444\u201352. https:\/\/doi.org\/10.1007\/s11655-011-0640-3.","journal-title":"Chin J Integr Med"},{"key":"2666_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107452","volume":"207","author":"L Zhang","year":"2020","unstructured":"Zhang L, Wei W. Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony. Pharmacol Ther. 2020;207: 107452. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107452.","journal-title":"Pharmacol Ther"},{"key":"2666_CR93","doi-asserted-by":"publisher","first-page":"153724","DOI":"10.1016\/j.phymed.2021.153724","volume":"92","author":"W Yu","year":"2021","unstructured":"Yu W, Zeng M, Xu P, Liu J, Wang H. Effect of paeoniflorin on acute lung injury induced by influenza A virus in mice. Evidences of its mechanism of action. Phytomedicine. 2021;92:153724. https:\/\/doi.org\/10.1016\/j.phymed.2021.153724.","journal-title":"Phytomedicine"},{"key":"2666_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118022","volume":"327","author":"Z Liu","year":"2024","unstructured":"Liu Z, Gao J, Ban Y, et al. Synergistic effect of paeoniflorin combined with luteolin in alleviating Lipopolysaccharides-induced acute lung injury. J Ethnopharmacol. 2024;327: 118022. https:\/\/doi.org\/10.1016\/j.jep.2024.118022.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"2666_CR95","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13020-020-00413-y","volume":"16","author":"C Junren","year":"2021","unstructured":"Junren C, Xiaofang X, Mengting L, et al. Pharmacological activities and mechanisms of action of Pogostemon cablin Benth: a review. Chin Med. 2021;16(1):5. https:\/\/doi.org\/10.1186\/s13020-020-00413-y.","journal-title":"Chin Med"},{"issue":"Pt A","key":"2666_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107056","volume":"89","author":"HS Lee","year":"2020","unstructured":"Lee HS, Lee J, Smolensky D, Lee SH. Potential benefits of patchouli alcohol in prevention of human diseases: a mechanistic review. Int Immunopharmacol. 2020;89(Pt A): 107056. https:\/\/doi.org\/10.1016\/j.intimp.2020.107056.","journal-title":"Int Immunopharmacol"},{"key":"2666_CR97","doi-asserted-by":"publisher","first-page":"938868","DOI":"10.3389\/fmicb.2022.938868","volume":"13","author":"Y Fan","year":"2023","unstructured":"Fan Y, Zhang Q, Zhang W, et al. Inhibitory effects of Patchouli alcohol on the early lifecycle stages of influenza A virus. Front Microbiol. 2023;13:938868. https:\/\/doi.org\/10.3389\/fmicb.2022.938868.","journal-title":"Front Microbiol"},{"issue":"1","key":"2666_CR98","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11418-011-0550-x","volume":"66","author":"H Kiyohara","year":"2012","unstructured":"Kiyohara H, Ichino C, Kawamura Y, Nagai T, Sato N, Yamada H. Patchouli alcohol: in vitro direct anti-influenza virus sesquiterpene in Pogostemon cablin Benth. J Nat Med. 2012;66(1):55\u201361. https:\/\/doi.org\/10.1007\/s11418-011-0550-x.","journal-title":"J Nat Med"},{"issue":"1","key":"2666_CR99","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12985-019-1266-x","volume":"16","author":"Y Yu","year":"2019","unstructured":"Yu Y, Zhang Y, Wang S, Liu W, Hao C, Wang W. Inhibition effects of patchouli alcohol against influenza a virus through targeting cellular PI3K\/Akt and ERK\/MAPK signaling pathways. Virol J. 2019;16(1):163. https:\/\/doi.org\/10.1186\/s12985-019-1266-x.","journal-title":"Virol J"},{"key":"2666_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.phytochem.2021.112854","volume":"190","author":"RB Semwal","year":"2021","unstructured":"Semwal RB, Semwal DK, Combrinck S, Viljoen A. Emodin-A natural anthraquinone derivative with diverse pharmacological activities. Phytochemistry. 2021;190: 112854. https:\/\/doi.org\/10.1016\/j.phytochem.2021.112854.","journal-title":"Phytochemistry"},{"issue":"8","key":"2666_CR101","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/ptr.5631","volume":"30","author":"X Dong","year":"2016","unstructured":"Dong X, Fu J, Yin X, et al. Emodin: a review of its pharmacology, toxicity and pharmacokinetics. Phytother Res. 2016;30(8):1207\u201318. https:\/\/doi.org\/10.1002\/ptr.5631.","journal-title":"Phytother Res"},{"key":"2666_CR102","doi-asserted-by":"publisher","first-page":"9066938","DOI":"10.1155\/2021\/9066938","volume":"2021","author":"Y Bei","year":"2021","unstructured":"Bei Y, Tia B, Li Y, et al. Anti-influenza A virus effects and mechanisms of emodin and its analogs via regulating PPAR\u03b1\/\u03b3-AMPK-SIRT1 pathway and fatty acid metabolism. Biomed Res Int. 2021;2021:9066938. https:\/\/doi.org\/10.1155\/2021\/9066938.","journal-title":"Biomed Res Int"},{"issue":"2","key":"2666_CR103","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10753-021-01581-1","volume":"45","author":"Y Liu","year":"2022","unstructured":"Liu Y, Shang L, Zhou J, Pan G, Zhou F, Yang S. Emodin attenuates LPS-induced acute lung injury by inhibiting NLRP3 inflammasome-dependent pyroptosis signaling pathway in vitro and in vivo. Inflammation. 2022;45(2):753\u201367. https:\/\/doi.org\/10.1007\/s10753-021-01581-1.","journal-title":"Inflammation"},{"issue":"10","key":"2666_CR104","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.3390\/molecules22101754","volume":"22","author":"JP Dai","year":"2017","unstructured":"Dai JP, Wang QW, Su Y, et al. Emodin inhibition of influenza A virus replication and influenza viral pneumonia via the Nrf2, TLR4, p38\/JNK and NF-kappaB pathways. Molecules. 2017;22(10):1754. https:\/\/doi.org\/10.3390\/molecules22101754.","journal-title":"Molecules"},{"issue":"9","key":"2666_CR105","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/10408398.2016.1263597","volume":"58","author":"A Rauf","year":"2018","unstructured":"Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: a review. Crit Rev Food Sci Nutr. 2018;58(9):1428\u201347. https:\/\/doi.org\/10.1080\/10408398.2016.1263597.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"1","key":"2666_CR106","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.intimp.2015.05.031","volume":"28","author":"N Zang","year":"2015","unstructured":"Zang N, Li S, Li W, et al. Resveratrol suppresses persistent airway inflammation and hyperresponsivess might partially via nerve growth factor in respiratory syncytial virus-infected mice. Int Immunopharmacol. 2015;28(1):121\u20138. https:\/\/doi.org\/10.1016\/j.intimp.2015.05.031.","journal-title":"Int Immunopharmacol"},{"key":"2666_CR107","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jep.2017.08.040","volume":"210","author":"Z Wang","year":"2018","unstructured":"Wang Z, Xia Q, Liu X, et al. Phytochemistry, pharmacology, quality control and future research of Forsythia suspensa (Thunb.) Vahl: A review. J Ethnopharmacol. 2018;210:318\u201339. https:\/\/doi.org\/10.1016\/j.jep.2017.08.040.","journal-title":"J Ethnopharmacol"},{"issue":"12","key":"2666_CR108","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.3390\/molecules27123670","volume":"27","author":"C Zhou","year":"2022","unstructured":"Zhou C, Lu M, Cheng J, et al. Review on the pharmacological properties of phillyrin. Molecules. 2022;27(12):3670. https:\/\/doi.org\/10.3390\/molecules27123670.","journal-title":"Molecules"},{"issue":"1","key":"2666_CR109","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.intimp.2015.07.011","volume":"28","author":"L Cheng","year":"2015","unstructured":"Cheng L, Li F, Ma R, Hu X. Forsythiaside inhibits cigarette smoke-induced lung inflammation by activation of Nrf2 and inhibition of NF-\u03baB. Int Immunopharmacol. 2015;28(1):494\u20139. https:\/\/doi.org\/10.1016\/j.intimp.2015.07.011.","journal-title":"Int Immunopharmacol"},{"key":"2666_CR110","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.fitote.2013.06.003","volume":"90","author":"WT Zhong","year":"2013","unstructured":"Zhong WT, Wu YC, Xie XX, et al. Phillyrin attenuates LPS-induced pulmonary inflammation via suppression of MAPK and NF-\u03baB activation in acute lung injury mice. Fitoterapia. 2013;90:132\u20139. https:\/\/doi.org\/10.1016\/j.fitote.2013.06.003.","journal-title":"Fitoterapia"},{"key":"2666_CR111","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jep.2017.07.015","volume":"209","author":"AH Law","year":"2017","unstructured":"Law AH, Yang CL, Lau AS, Chan GC. Antiviral effect of forsythoside A from Forsythia suspensa (Thunb.) Vahl fruit against influenza A virus through reduction of viral M1 protein. J Ethnopharmacol. 2017;209:236\u201347. https:\/\/doi.org\/10.1016\/j.jep.2017.07.015.","journal-title":"J Ethnopharmacol."},{"key":"2666_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153296","volume":"78","author":"Q Ma","year":"2020","unstructured":"Ma Q, Li R, Pan W, et al. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-\u03baB) signaling pathway. Phytomedicine. 2020;78: 153296. https:\/\/doi.org\/10.1016\/j.phymed.2020.153296.","journal-title":"Phytomedicine"},{"key":"2666_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107618","volume":"214","author":"C Bailly","year":"2020","unstructured":"Bailly C, Vergoten G. Glycyrrhizin: an alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Pharmacol Ther. 2020;214: 107618. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107618.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"2666_CR114","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/ptr.6852","volume":"35","author":"J Chrzanowski","year":"2021","unstructured":"Chrzanowski J, Chrzanowska A, Grabo\u0144 W. Glycyrrhizin: an old weapon against a novel coronavirus. Phytother Res. 2021;35(2):629\u201336. https:\/\/doi.org\/10.1002\/ptr.6852.","journal-title":"Phytother Res"},{"issue":"9374","key":"2666_CR115","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/s0140-6736(03)13615-x","volume":"361","author":"J Cinatl","year":"2003","unstructured":"Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361(9374):2045\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(03)13615-x.","journal-title":"Lancet"},{"issue":"16","key":"2666_CR116","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.2174\/1389557521666210210160237","volume":"21","author":"H Al-Kamel","year":"2021","unstructured":"Al-Kamel H, Grundmann O. Glycyrrhizin as a potential treatment for the novel coronavirus (COVID-19). Mini Rev Med Chem. 2021;21(16):2204\u20138. https:\/\/doi.org\/10.2174\/1389557521666210210160237.","journal-title":"Mini Rev Med Chem"},{"issue":"1","key":"2666_CR117","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","volume":"31","author":"F Chen","year":"2004","unstructured":"Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31(1):69\u201375. https:\/\/doi.org\/10.1016\/j.jcv.2004.03.003.","journal-title":"J Clin Virol"},{"key":"2666_CR118","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3389\/fimmu.2020.01239","volume":"11","author":"H Murck","year":"2020","unstructured":"Murck H. Symptomatic protective action of glycyrrhizin (Licorice) in COVID-19 infection? Front Immunol. 2020;11:1239. https:\/\/doi.org\/10.3389\/fimmu.2020.01239.","journal-title":"Front Immunol"},{"issue":"1","key":"2666_CR119","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/jcmm.14703","volume":"24","author":"L Zheng","year":"2020","unstructured":"Zheng L, Zhu Q, Xu C, et al. Glycyrrhizin mitigates radiation-induced acute lung injury by inhibiting the HMGB1\/TLR4 signalling pathway. J Cell Mol Med. 2020;24(1):214\u201326. https:\/\/doi.org\/10.1111\/jcmm.14703.","journal-title":"J Cell Mol Med"},{"issue":"8","key":"2666_CR120","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1875-5364(23)60401-7","volume":"21","author":"Q Huang","year":"2023","unstructured":"Huang Q, Wang M, Wang M, et al. Scutellaria baicalensis: a promising natural source of antiviral compounds for the treatment of viral diseases. Chin J Nat Med. 2023;21(8):563\u201375. https:\/\/doi.org\/10.1016\/S1875-5364(23)60401-7.","journal-title":"Chin J Nat Med"},{"key":"2666_CR121","doi-asserted-by":"publisher","first-page":"110917","DOI":"10.1016\/j.biopha.2020.110917","volume":"133","author":"H Liao","year":"2021","unstructured":"Liao H, Ye J, Gao L, Liu Y. The main bioactive compounds of Scutellaria baicalensis Georgi for alleviation of inflammatory cytokines: a comprehensive review. Biomed Pharmacother. 2021;133:110917. https:\/\/doi.org\/10.1016\/j.biopha.2020.110917.","journal-title":"Biomed Pharmacother"},{"key":"2666_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115629","volume":"258","author":"B Dinda","year":"2023","unstructured":"Dinda B, Dinda M, Dinda S, De UC. An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: insights into molecular mechanisms. Eur J Med Chem. 2023;258: 115629. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115629.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"2666_CR123","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3390\/molecules28041873","volume":"28","author":"B Shen","year":"2023","unstructured":"Shen B, Zhang H, Zhu Z, et al. Baicalin relieves LPS-induced lung inflammation via the NF-\u03baB and MAPK pathways. Molecules. 2023;28(4):1873. https:\/\/doi.org\/10.3390\/molecules28041873.","journal-title":"Molecules"},{"issue":"12","key":"2666_CR124","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00705-014-2192-2","volume":"159","author":"Y Ding","year":"2014","unstructured":"Ding Y, Dou J, Teng Z, et al. Antiviral activity of baicalin against influenza A (H1N1\/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase. Arch Virol. 2014;159(12):3269\u201378. https:\/\/doi.org\/10.1007\/s00705-014-2192-2.","journal-title":"Arch Virol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02666-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02666-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02666-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T19:40:33Z","timestamp":1741290033000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02666-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2666"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02666-1","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}